Visual Reality: Diabetic Retinopathy

1.00 COPE
$0 FEE
Visual Reality: Diabetic Retinopathy OG Image Size


Provider Statement

This continuing education activity is provided by Purdue U.

Educational Partner

Vindico Medical Education

Support Statement

This activity is supported by independent medical education grants from Optos North America and Regeneron Pharmaceuticals, Inc.

Target Audience

The intended audience for this activity is optometrists and other health care professionals involved in the management of patients with, or at risk for, diabetic retinopathy (DR).

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Review the pathophysiology behind DR to better understand how its underlying mechanisms can be targeted with treatment.
  • Assess current methods used to screen patients for diabetes and DR to aid in the prevention of vision loss.
  • Evaluate evidence-based methods to diagnose and assess DR so that treatment can be initiated earlier.
  • Identify patients who are candidates for referral to specialists for treatment of vision-threatening diabetic retinal disease.
  • Examine therapeutic regimens that may improve outcomes in patients with DR.
  • Describe patient education techniques and tools that can effectively improve adherence and compliance to therapy.

Activity Chair

Rishi P. Singh, MD
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH


Mark T. Dunbar, OD, FAAO
Director of Optometric Services
Bascom Palmer Eye Institute
UHealth – University of Miami Health System
Miami, FL

Andrew A. Moshfeghi, MD, MBA
Director, Vitreoretinal Surgery & Medical Retina Fellowships
Director, Clinical Trials Unit
Associate Professor of Ophthalmology
USC Roski Eye Institute
Keck School of Medicine
University of Southern California
Los Angeles, CA


Ashay Bhatwadekar, MPharm, PhD

Medical Writer

Valerie Zimmerman, PhD


Purdue University is approved by the Council on Optometric Practitioner Education (COPE) as an administrator/provider of continuing education (CE).

Credit Designation

This enduring material is COPE-accredited for 1.0 continuing education credit and is approved for one (1) year from the date of original release, June 1, 2019 to June 1, 2020.

COPE ID #: 62412-PS
COPE Event #: 117369

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.

How to Participate in This Activity and Obtain CE Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, read the articles, and complete the CE posttest and evaluation in their entirety. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Purdue University will issue a CE certificate.


In accordance with the Council on Optometric Practitioner Education Standards for Commercial Support, all CE providers are required to disclose to the activity audience the relevant financial relationships of the planners, authors, reviewers, and staff involved in the development of CE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CE activity content over which the individual has control. Relationship information appears on this page.

The articles in this monograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Dunbar, Moshfeghi, and Singh at the COPE-accredited live meeting held on December 8, 2018, in Chicago, Illinois.

Activity Chair and Faculty report the following relationship(s)

Mark T. Dunbar, OD, FAAO
Consulting Fee: Allergan, Genentech, Notal Vision, Regeneron, Zeiss
Speakers Bureau: Allergan, Genentech, Regeneron, Zeiss

Andrew A. Moshfeghi, MD, MBA
Consulting Fee: Alcon, Allegro, Allergan, Clearside, EyePoint, Genentech/Roche, Novartis, Pr3vent, Regeneron, Valeant/Bausch + Lomb
Contracted Research: Genentech/Roche, Regeneron
Ownership Interest: OptiSTENT, Pr3vent, Visunex

Rishi P. Singh, MD
Consulting Fee: Alcon, Genentech, Optos, Regeneron, Zeiss
Contracted Research: Alcon, Apellis, Genentech, Regeneron

Reviewer reports the following relationship(s)

Ashay Bhatwadekar, MPharm, PhD
No relevant financial relationships to disclose.

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Purdue University and Vindico Medical Education staff report the following relationships

No relevant financial relationships to disclose.

Signed disclosures are on file at Purdue University and Vindico Medical Education, Office of Medical Affairs Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Purdue University and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Purdue University and Vindico Medical Education. Neither Purdue University, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product. 

CE Questions?

Contact us at: 
Purdue University: or 765-496-1306.
Vindico Medical Education: or 856-994-9400, ext. 504.


In accordance with the Sunshine Act, effective August 1, 2013, the medical device or pharmaceutical manufacturer that provided support for this CE activity is required to disclose to the federal government the names of physician-participants and the value received for this CE activity. While Purdue University and Vindico Medical Education are not responsible for making this report, as our valued customer we want to advise you that by partaking in this program, your name and the computed value of this monograph in the amount of $15.00 may be posted on a website accessible to the public. For more information on this Sunshine Act’s effects on physicians, please visit this web page:

CE and Sunshine Act Attestation

I certify that I have personally completed this activity and the posttest/evaluation. I understand that this is not considered CEE and that each state board of optometry defines a limit to the number of hours of verified self-instruction per renewal period. I also understand that this attestation may be used by a state’s regulatory body for license renewal, and I attest that by submission of this registration form I may be reported to the federal government as receiving a transfer or value in the amount of $15.00 for participating in this CE activity.